The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor‐positive breast cancer von Thaler, Sonja, Thiede, Gitta, Hengstler, Jan G., Schad, Arno, Schmidt, Marcus, Sleeman, Jonathan P.

Volltext

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Ac... von Roßwag, Sven, Thiede, Gitta, Sleeman, Jonathan P., Thaler, Sonja

Volltext

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 von Ro[beta]wag, Sven, Thiede, Gitta, Sleeman, Jonathan P, Thaler, Sonja

Volltext

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells von Thaler, Sonja, Schmidt, Marcus, Roβwag, Sven, Thiede, Gitta, Schad, Arno, Sleeman, Jonathan P

Volltext

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer: ER+ breast cancer therapy von Thaler, Sonja, Thiede, Gitta, Hengstler, Jan G., Schad, Arno, Schmidt, Marcus, Sleeman, Jonathan P.

Volltext